NVS241220P70000
- 0.05
- 0.000.00%
Novartis AG Newsroom
ptc therapeutics (PTCT.US) and novartis ag (NVS.US) sign huntington's disease drug licensing agreement
The stock price of ptc therapeutics (PTCT.US) rose 21% in pre-market trading on Monday.
Janux, Vir Stocks Rally on Positive Data for Janux Drug JANX007
PTC Upgraded to Outperform by RBC on Novartis Deal
Olema in Deal With Novartis on Kisqali Breast Cancer Combo Collaboration
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Sector Update: Health Care
PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones
Press Release: Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement
Novartis AG (NVS): A Bull Case Theory
Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Wedbush Assumes Coverage of Voyager With Outperform Rating
Trump 'sells off' European pharmaceutical stocks, can only rely on 'Americanization' to stop the decline?
The growth prescription for European pharmaceutical companies: shifting towards the usa.
Express News | The annual pharmaceutical imports value of Peking Tianzhu Comprehensive Bonded Zone is approximately 120 billion yuan.
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Express News | Innovent Bio's PCSK9-targeted lipid-lowering drug has entered the new version of the medical insurance catalog.
Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to revolutionize the treatment of early-stage breast cancer.
Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.
European Commission Approves Products by BeiGene, GSK and Novartis
The European Commission Has Approved Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer At High Risk...